H.C. Wainwright upgraded MiNK Therapeutics to Buy from Neutral with an unchanged price target of $35 post the Q2 report. The firm sees the company's Phase 2 gastric cancer data later this year as a "significant catalyst" for the shares. The majority of patients in the Phase 2 gastric study are now enrolled and initial efficacy data is expected in the back half of the year, the analyst tells investors in a research note. H.C. Wainwright points out MiNK shares are now well below its price target.
